Global Blood Therapeutics (GBT) Given Daily News Impact Score of 0.17

Media stories about Global Blood Therapeutics (NASDAQ:GBT) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Global Blood Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.8465808354059 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

GBT has been the topic of a number of research analyst reports. Cowen restated a “buy” rating and set a $83.00 price target on shares of Global Blood Therapeutics in a report on Thursday, November 9th. Wedbush restated an “ourperform” rating and set a $73.00 price target on shares of Global Blood Therapeutics in a report on Monday, September 18th. Zacks Investment Research downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Oppenheimer set a $53.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a report on Monday, November 13th. Finally, ValuEngine downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $62.07.

Shares of Global Blood Therapeutics (GBT) opened at $37.45 on Thursday. Global Blood Therapeutics has a 12-month low of $13.35 and a 12-month high of $45.85.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.04). During the same quarter last year, the company earned ($0.58) earnings per share. equities analysts forecast that Global Blood Therapeutics will post -2.55 EPS for the current year.

In related news, major shareholder Perceptive Advisors Llc purchased 175,000 shares of the company’s stock in a transaction dated Tuesday, December 19th. The shares were purchased at an average cost of $38.00 per share, with a total value of $6,650,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Charles J. Homcy sold 70,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now directly owns 83,328 shares in the company, valued at $2,830,652.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 91,500 shares of company stock worth $3,113,000. Insiders own 5.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Global Blood Therapeutics (GBT) Given Daily News Impact Score of 0.17” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/21/global-blood-therapeutics-gbt-given-daily-news-impact-score-of-0-17.html.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Insider Buying and Selling by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit